Bowen Hanes & Co’s Quest Diagnostics DGX Stock Holding History

Bowen Hanes & Co’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,000	Closed	-$416K	–	153
2018 Q4	$416K	Buy	+5,000	New	+$469K	0.02%	145

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bowen Hanes & Co's DGX Position: Q1 2019 in Review

Bowen Hanes & Co sold out of Quest Diagnostics (DGX) in Q1 2019, closing a stake of 5,000 shares — an estimated $416K sold.

Bowen Hanes & Co first reported a position in DGX in Q4 2018 and held it in 1 quarter. The position peaked at $416K in Q4 2018. 656 funds tracked by Wall St. Rank hold DGX as of Q1 2019.

Bowen Hanes & Co reported no remaining Quest Diagnostics position as of Q1 2019 after selling out during the quarter.
Bowen Hanes & Co sold 5,000 Quest Diagnostics shares in Q1 2019, an estimated $416K.
Bowen Hanes & Co first reported a position in Quest Diagnostics in Q4 2018 and held it in 1 quarter.
Bowen Hanes & Co's Quest Diagnostics position peaked at $416K in Q4 2018.
656 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2019.

Based on Bowen Hanes & Co's 13F filing for Q1 2019, filed 13 May 2019.